Diseases
Companies
Products
Productz
Mechanisms of Action
Sites
resomelagon
(AP1189) /
SynAct Pharma
Welcome,
Profile
Billing
Logout
0 Diseases
2 Trials
2 Trials
58 News
|||
|||||||
resomelagon
(AP1189) /
SynAct Pharma
Trial completion:
EXPAND: A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients na
(clinicaltrials.gov) - Nov 7, 2023
P2
, N=127, Completed,
Sponsor: SynAct Pharma Aps
Recruiting --> Completed
||||
||||||
resomelagon
(AP1189) /
SynAct Pharma
Enrollment open:
RESOLVE: A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
(clinicaltrials.gov) - Jan 9, 2023
P2
, N=420, Recruiting,
Sponsor: SynAct Pharma Aps
Recruiting --> Completed Not yet recruiting --> Recruiting
|
|||||||||
resomelagon
(AP1189) /
SynAct Pharma
Trial primary completion date:
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
(clinicaltrials.gov) - Nov 17, 2022
P2
, N=23, Recruiting,
Sponsor: SynAct Pharma Aps
Not yet recruiting --> Recruiting Trial primary completion date: Nov 2022 --> Dec 2023
|||||
|||||
resomelagon
(AP1189) /
SynAct Pharma
New P2 trial:
RESOLVE: A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate
(clinicaltrials.gov) - Nov 3, 2022
P2
, N=420, Not yet recruiting,
Sponsor: SynAct Pharma Aps
|
|||||||||
resomelagon
(AP1189) /
SynAct Pharma
Trial completion date:
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
(clinicaltrials.gov) - Oct 27, 2022
P2
, N=23, Recruiting,
Sponsor: SynAct Pharma Aps
Trial primary completion date: Nov 2022 --> Dec 2023 Trial completion date: Dec 2022 --> Dec 2023
|||
|||||||
resomelagon
(AP1189) /
SynAct Pharma
Enrollment open:
EXPAND: A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients na
(clinicaltrials.gov) - Sep 28, 2022
P2
, N=120, Recruiting,
Sponsor: SynAct Pharma Aps
Trial completion date: Dec 2022 --> Dec 2023 Not yet recruiting --> Recruiting
||||||||||
AP1189
/
SynAct Pharma
The BEGIN Study: A Double-blind, Multi-center, Two-part, Randomized, Placebo-controlled Study of the Safety, Tolerability, and Efficacy of 4 Weeks of Treatment with AP1189 in Early Rheumatoid Arthritis (RA) Patients with Active Joint Disease
(Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_1883;
AP1189 is novel oral available compound with anti-inflammatory and pro-resolving effects with the potential to treat active RA. Data from the BEGIN study support the further development of AP1189 as a potential safe and efficacious oral therapy for RA and other inflammatory diseases
||||
||||||
resomelagon
(AP1189) /
SynAct Pharma
New P2 trial:
EXPAND: A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients na
(clinicaltrials.gov) - Aug 26, 2022
P2
, N=120, Not yet recruiting,
Sponsor: SynAct Pharma Aps
|||
|||||||
AP1189
/
SynAct Pharma
Clinical, PK/PD data:
SynAct Pharma completes clinical pharmacokinetic test of AP1189 tablet https://t.co/WNUoJTJfdy
(Twitter) - May 3, 2022
|||
|||||||
resomelagon
(AP1189) /
SynAct Pharma
Trial completion:
SynAct-CS002: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
(clinicaltrials.gov) - Nov 29, 2021
P2
, N=105, Completed,
Sponsor: SynAct Pharma Aps
Data from the BEGIN study support the further development of AP1189 as a potential safe and efficacious oral therapy for RA and other inflammatory diseases Active, not recruiting --> Completed
|||
|||||||
AP1189
/
SynAct Pharma
PK/PD data:
SynAct Pharma reports positive PK data on AP1189 tablets https://t.co/iLwUCAaeer
(Twitter) - Nov 22, 2021
||
||||||||
AP1189
/
SynAct Pharma
SynAct Pharma drar nytta av nya toxikologiska resultat och ny tablettformulering för att omdesigna och optimera studieprogrammet med AP1189 i nefrotiskt syndrom https://t.co/B2SCdIZFHN
(Twitter) - Nov 10, 2021
||
||||||||
Yselty
(linzagolix) /
ObsEva, Kissei
,
QR-1123
/
Ionis, ProQR
,
AP1189
/
SynAct Pharma
$SYNACT: AP1189 Ph2 data in RA - Nov'21 $OBSN: Linzagolix Ph3 data in endometriosis - Q4'21 $PRQR: QR-1123 Ph1/2 in adRP - Q4'21 Conferences #ACAAI21 - 4-8 Nov CHMP Meeting - 8-12 Nov #CTAD21 - 9-12 Nov (3/4)
(Twitter) - Nov 8, 2021
||
||||||||
AP1189
/
SynAct Pharma
Clinical:
AP1189 can be dosed for three months in future clinical studies https://t.co/1nhuFciHe7
(Twitter) - Nov 4, 2021
|
|||||||||
AP1189
/
SynAct Pharma
AP1189 kan doseras i tre månader i framtida kliniska studier https://t.co/fo1iN4IjSZ
(Twitter) - Nov 4, 2021
||
||||||||
AP1189
/
SynAct Pharma
SynAct Pharma doserar första försöksperson i studie med nya AP1189-tabletter https://t.co/fA1EZmfeTl
(Twitter) - Oct 15, 2021
||
||||||||
resomelagon
(AP1189) /
SynAct Pharma
Enrollment closed:
SynAct-CS002: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
(clinicaltrials.gov) - Oct 11, 2021
P2
, N=135, Active, not recruiting,
Sponsor: SynAct Pharma Aps
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
|
|||||||||
resomelagon
(AP1189) /
SynAct Pharma
Trial completion date, Trial primary completion date:
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
(clinicaltrials.gov) - Sep 21, 2021
P2
, N=23, Recruiting,
Sponsor: SynAct Pharma Aps
Recruiting --> Active, not recruiting Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Nov 2021 --> Nov 2022
||||||||||
AP1189
/
SynAct Pharma
[VIRTUAL] AP1189: A Novel Oral Biased Melanocortin Agonist with Anti-inflammatory and Pro-resolving Effect for the Treatment of Rheumatoid Arthritis
() - Sep 21, 2021 - Abstract #ACRCONVERGENCE2021ACR_CONVERGENCE_1912;
9 were treated with placebo, 9 with 50 mg AP1189 and 8 with 100 mg AP1189 as add on to the MTX treatment. There were no dropouts, and no serious adverse events were observed.
|||
|||||||
AP1189
/
SynAct Pharma
Clinical:
SynAct Pharma ger en uppdatering om patientrekrytering i den kliniska fas 2a-studien med AP1189 i reumatoid artrit https://t.co/Seo34jnB64
(Twitter) - Aug 26, 2021
|||
|||||||
AP1189
/
SynAct Pharma
SynAct Pharma to present new data on AP1189 for the treatment of rheumatoid arthritis at ACR Convergence 2021 https://t.co/Zyu0gLSyDZ
(Twitter) - Aug 19, 2021
||
||||||||
AP1189
/
SynAct Pharma
SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations https://t.co/shv324mJcs
(Twitter) - Jun 22, 2021
|||
|||||||
resomelagon
(AP1189) /
SynAct Pharma
Enrollment change, Trial completion date, Trial primary completion date:
SynAct-CS002: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
(clinicaltrials.gov) - May 4, 2021
P2
, N=135, Recruiting,
Sponsor: SynAct Pharma Aps
There were no dropouts, and no serious adverse events were observed. N=90 --> 135 | Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Mar 2021 --> Dec 2021
|||
|||||||
AP1189
/
SynAct Pharma
SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version https://t.co/ELxQ6iWVqv
(Twitter) - May 3, 2021
||
||||||||
resomelagon
(AP1189) /
SynAct Pharma
New P2 trial:
A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria
(clinicaltrials.gov) - Jul 6, 2020
P2
, N=23, Recruiting,
Sponsor: SynAct Pharma Aps
|
|||||||||
resomelagon
(AP1189) /
SynAct Pharma
New P2 trial:
SynAct-CS002: A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease
(clinicaltrials.gov) - Jul 1, 2019
P2
, N=90, Recruiting,
Sponsor: SynAct Pharma Aps